StockData
Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc. (XLO) stock

XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.54−0.16 (-2.08%)

Close on Nov 17, 2026Market cap $43.60MP/E –Yield –

Xilio Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Xilio Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$60.60M. For fiscal 2025 it was -$4.99M. The highest annual figure on record is -$4.99M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$4.99M–
FY2024Dec 31, 2024-$18.38M–
FY2023Dec 31, 2023-$68.62M–
FY2022Dec 31, 2022-$75.72M–
FY2021Dec 31, 2021-$80.75M–
FY2020Dec 31, 2020-$36.09M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$18.76M–
Q1 FY2026Mar 31, 2026-$22.34M-177.1%
Q4 FY2025Dec 31, 2025-$2.00M–
Q3 FY2025Sep 30, 2025-$17.50M–
Q2 FY2025Jun 30, 2025-$14.48M-172.6%
Q1 FY2025Mar 31, 2025$28.98M–
Q4 FY2024Dec 31, 2024-$14.16M–
Q3 FY2024Sep 30, 2024-$13.67M–
Q2 FY2024Jun 30, 2024$19.95M–
Q1 FY2024Mar 31, 2024-$10.50M–
Q4 FY2023Dec 31, 2023-$13.43M–
Q3 FY2023Sep 30, 2023-$13.37M–
Q2 FY2023Jun 30, 2023-$16.57M–
Q1 FY2023Mar 31, 2023-$25.25M–
Q4 FY2022Dec 31, 2022-$18.22M–
Q3 FY2022Sep 30, 2022-$19.91M–
Q2 FY2022Jun 30, 2022-$16.76M–
Q1 FY2022Mar 31, 2022-$20.84M–
Q4 FY2021Dec 31, 2021-$17.16M–
Q3 FY2021Sep 30, 2021-$20.72M–
Q2 FY2021Jun 30, 2021-$20.14M–
Q1 FY2021Mar 31, 2021-$22.73M–
Q4 FY2020Dec 31, 2020-$12.71M–

More Xilio Therapeutics figures

See a number that looks wrong?